Barclays Maintains Overweight on Globus Medical, Raises Price Target to $86
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Matt Miksic maintains an Overweight rating on Globus Medical (NYSE:GMED) and raises the price target from $77 to $86.
October 12, 2023 | 6:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays maintains an Overweight rating on Globus Medical and raises the price target from $77 to $86, which could lead to a positive market reaction.
The raised price target by Barclays indicates a positive outlook for Globus Medical. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100